By David McAfee ( November 22, 2013, 8:11 PM EST) -- A Delaware federal judge has ruled against Exela Pharma Sciences LLC and its subsidiaries in favor of Cadence Pharmaceuticals Inc. in a patent infringement suit over plans to market a generic version of the injectable pain reliever Ofirmev, according to an opinion unsealed on Friday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.